Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug

All NewsApril 13, 2026

Spyre Therapeutics stock jumps after Phase 2 SKYLINE data; SPY001 shows efficacy in ulcerative colitis as analysts maintain bullish outlook.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent